Trevi Therapeutics
TRVI
40 hedge funds and large institutions have $70.5M invested in Trevi Therapeutics in 2022 Q3 according to their latest regulatory filings, with 11 funds opening new positions, 14 increasing their positions, 10 reducing their positions, and 3 closing their positions.
267% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 3
40% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 10
25% more funds holding
Funds holding: 32 → 40 (+8)
4.17% more ownership
Funds ownership: 74.31% → 78.48% (+4.2%)
13% less capital invested
Capital invested by funds: $80.8M → $70.5M (-$10.3M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Viking Global Investors
Stamford,
Connecticut
|
+$14.4M |
| 2 |
FLSM
Frazier Life Sciences Management
Palo Alto,
California
|
+$13.9M |
| 3 |
FFM
Fairmount Funds Management
West Conshohocken,
Pennsylvania
|
+$13.4M |
| 4 |
RCMNY
Rubric Capital Management (New York)
New York
|
+$12.8M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$4.84M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TGA
TPG GP A
Fort Worth,
Texas
|
-$13.4M |
| 2 |
EI
EAM Investors
Solana Beach,
California
|
-$1.03M |
| 3 |
ACM
Altium Capital Management
New York
|
-$714K |
| 4 |
JGC
J. Goldman & Co
New York
|
-$150K |
| 5 |
Millennium Management
New York
|
-$86K |
TRVI Hedge Fund Activity: Q3 2022 in Review
40 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in Trevi Therapeutics (TRVI) for Q3 2022, worth a combined $70.5M — down 13% from $80.8M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new TRVI positions and 3 closed out — a net gain of 8 holders — while 14 added to existing stakes and 10 trimmed.
The largest buyer was Viking Global Investors, opening a new position worth an estimated $14.4M. The largest seller was TPG GP A, cutting an estimated $13.4M.
- 40 institutional investors held Trevi Therapeutics (TRVI) as of Q3 2022, up from 32 in Q2 2022.
- Funds reported $70.5M of Trevi Therapeutics stock for Q3 2022, down 13% quarter-over-quarter.
- 11 funds opened new Trevi Therapeutics positions in Q3 2022 and 3 closed out, a net change of +8 holders.
- The largest Trevi Therapeutics buyer in Q3 2022 was Viking Global Investors, an estimated $14.4M added.
- The largest Trevi Therapeutics seller in Q3 2022 was TPG GP A, an estimated $13.4M sold.
Based on aggregated 13F filings for Q3 2022.